Chaochu Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chaochu Cui has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Xianwei Wang
Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang 453003, China
4 shared publications - Zui Pan
Bone-Muscle Research Center, College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX 76019, USA
4 shared publications Gang Liu
Henan Key Laboratory of Medical Tissue Regeneration, College of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China
2 shared publicationsJianbo Yang
Henan Key Laboratory of Medical Tissue Regeneration, College of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China
2 shared publicationsJinyu Zhao
Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, Henan, People’s Republic of China
2 shared publications- Liwu Fu
Sun Yat-sen University Cancer Center
2 shared publications
Latest Publications
- Open Access
- 1 March 2025
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 18, 411-427
PCSK9 Manipulates Lipid Metabolism and the Immune Microenvironment in Cancer
Cancer remains the foremost cause of mortality on a global scale. Immunotherapy has yielded remarkable outcomes in the fight against cancer and is regarded as one of the most crucial and promising therapeutic modalities. PCSK9, a critical target for plasma lipids control, has been extensively and deeply studied in multiple diseases. Currently, the functions of PCSK9 in cancer, particularly its immunomodulatory role, have been progressively revealed. PCSK9 is capable of modulating a variety of immune response throughout tumor progression by orchestrating lipid metabolism. Moreover, PCSK9 governs the cell fate of diverse immune cells, such as inflammatory factor signals, MHC signals, and TCR signals. This review comprehensively summarizes the current state of knowledge regarding the role and underlying mechanisms of PCSK9 in tumorigenesis, progression, immune escape, and drug resistance.
- 1 March 2025
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 18, 411-427
Open AccessPCSK9 Manipulates Lipid Metabolism and the Immune Microenvironment in Cancer
Cancer remains the foremost cause of mortality on a global scale. Immunotherapy has yielded remarkable outcomes in the fight against cancer and is regarded as one of the most crucial and promising therapeutic modalities. PCSK9, a critical target for plasma lipids control, has been extensively and deeply studied in multiple diseases. Currently, the functions of PCSK9 in cancer, particularly its immunomodulatory role, have been progressively revealed. PCSK9 is capable of modulating a variety of immune response throughout tumor progression by orchestrating lipid metabolism. Moreover, PCSK9 governs the cell fate of diverse immune cells, such as inflammatory factor signals, MHC signals, and TCR signals. This review comprehensively summarizes the current state of knowledge regarding the role and underlying mechanisms of PCSK9 in tumorigenesis, progression, immune escape, and drug resistance.
- Open Access
- 21 November 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (11)
Research Progress on the Pharmacological Effects and Molecular Mechanisms of Pinostrobin
Pinostrobin (5-hydroxy-7-methoxyflavanone) is an active flavonoid substance. It is widely present in many traditional Chinese herbs, including Carya cathayensis leaves, Boesenbergia rotunda and propolis. Pinostrobin possesses many pharmacological activities without significant toxicity. In addition to anti-inflammatory and antioxidant effects, pinostrobin also exerts antitumor effects. Pinostrobin is able to protect against infection by several viruses, bacteria, fungi, and parasites. Pinostrobin reduces the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a promising target of lipid-lowering drugs. It also reduces high uric acid levels while not affecting the normal uric acid levels. Furthermore, it has protective effects on the liver, kidney, bone, skin, reproductive system, stomach and nerves. Due to its multifunctional effects and safety, pinostrobin has advantages for development as a novel drug for clinical application. Based on this, this current article summarized the research progress on the pharmacological effects and mechanisms of pinostrobin, to provide a reference for further development.
- 21 November 2023
- Published by SAGE Publications in Natural Product Communications
- Vol. 18 (11)
Open AccessResearch Progress on the Pharmacological Effects and Molecular Mechanisms of Pinostrobin
Pinostrobin (5-hydroxy-7-methoxyflavanone) is an active flavonoid substance. It is widely present in many traditional Chinese herbs, including Carya cathayensis leaves, Boesenbergia rotunda and propolis. Pinostrobin possesses many pharmacological activities without significant toxicity. In addition to anti-inflammatory and antioxidant effects, pinostrobin also exerts antitumor effects. Pinostrobin is able to protect against infection by several viruses, bacteria, fungi, and parasites. Pinostrobin reduces the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a promising target of lipid-lowering drugs. It also reduces high uric acid levels while not affecting the normal uric acid levels. Furthermore, it has protective effects on the liver, kidney, bone, skin, reproductive system, stomach and nerves. Due to its multifunctional effects and safety, pinostrobin has advantages for development as a novel drug for clinical application. Based on this, this current article summarized the research progress on the pharmacological effects and mechanisms of pinostrobin, to provide a reference for further development.
- 10 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt B) , 111025
Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC
- 10 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 124 (Pt B) , 111025
Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC
- Open Access
- 28 June 2021
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (3) , 266-291
Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
Metastasis is still the primary cause of cancer-related mortality. However, the underlying mechanisms of cancer metastasis are not yet fully understood. Currently, the epithelial-mesenchymal transition, metabolic remodeling, cancer cell intercommunication and the tumor microenvironment including diverse stromal cells, are reported to affect the metastatic process of cancer cells. Calcium ions (Ca2+) are ubiquitous second messengers that manipulate cancer metastasis by affecting signaling pathways. Diverse transporter/pump/channel-mediated Ca2+ currents form Ca2+ oscillations that can be decoded by Ca2+-binding proteins, which are promising prognostic biomarkers and therapeutic targets of cancer metastasis. This paper presents a review of the advances in research on the mechanisms underlying cancer metastasis and the roles of Ca2+-related signals in these events.
- 28 June 2021
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (3) , 266-291
Open AccessAdvances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
Metastasis is still the primary cause of cancer-related mortality. However, the underlying mechanisms of cancer metastasis are not yet fully understood. Currently, the epithelial-mesenchymal transition, metabolic remodeling, cancer cell intercommunication and the tumor microenvironment including diverse stromal cells, are reported to affect the metastatic process of cancer cells. Calcium ions (Ca2+) are ubiquitous second messengers that manipulate cancer metastasis by affecting signaling pathways. Diverse transporter/pump/channel-mediated Ca2+ currents form Ca2+ oscillations that can be decoded by Ca2+-binding proteins, which are promising prognostic biomarkers and therapeutic targets of cancer metastasis. This paper presents a review of the advances in research on the mechanisms underlying cancer metastasis and the roles of Ca2+-related signals in these events.
- 27 August 2020
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 26 (1) , 3-11
Endothelial-to-Mesenchymal Transition: Role in Cardiac Fibrosis
Endothelial-to-mesenchymal transition (EndMT) is a complex biological process by which endothelial cells lose their endothelial cell characteristics and acquire mesenchymal cell properties under certain physiological or pathological conditions. Recently, it has been found that EndMT plays an important role in the occurrence and development of fibrotic cardiovascular diseases. In this review, we first summarize the main induction pathways involved in EndMT process. In addition, we discuss the role of EndMT in fibrotic cardiovascular diseases and its potential implication in new therapeutic interventions.
- 27 August 2020
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 26 (1) , 3-11
Endothelial-to-Mesenchymal Transition: Role in Cardiac Fibrosis
Endothelial-to-mesenchymal transition (EndMT) is a complex biological process by which endothelial cells lose their endothelial cell characteristics and acquire mesenchymal cell properties under certain physiological or pathological conditions. Recently, it has been found that EndMT plays an important role in the occurrence and development of fibrotic cardiovascular diseases. In this review, we first summarize the main induction pathways involved in EndMT process. In addition, we discuss the role of EndMT in fibrotic cardiovascular diseases and its potential implication in new therapeutic interventions.
- 22 February 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (9) , 1190-1205
Progress in understanding mitochondrial calcium uniporter complex‐mediated calcium signalling: A potential target for cancer treatment
Due to its Ca2+buffering capacity, the mitochondrion is one of the most important intracellular organelles in regulating Ca2+dynamic oscillation. Mitochondrial calcium uniporter (MCU) is the primary mediator of Ca2+influx into mitochondria, manipulating cell energy metabolism, ROS production, and programmed cell death, all of which are critical for carcinogenesis. The understanding of the uniporter complex was significantly boosted by recent groundbreaking discoveries that identified the uniporter pore‐forming subunit MCU and its regulatory molecules, including MCU‐dominant negative β subunit (MCUb), essential MCU regulator (EMRE), MCU regulator 1 (MCUR1), mitochondrial calcium uptake (MICU) 1, MICU2, and MICU3. These provide the means and molecular platform to investigate MCU complex (uniplex)‐mediated impaired Ca2+signalling in physiology and pathology. This review aims to summarize the progress of the understanding regulatory mechanisms of uniplex, roles of uniplex‐mediated Ca2+signalling in cancer, and potential pharmacological inhibitors of MCU.
- 22 February 2019
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (9) , 1190-1205
Progress in understanding mitochondrial calcium uniporter complex‐mediated calcium signalling: A potential target for cancer treatment
Due to its Ca2+buffering capacity, the mitochondrion is one of the most important intracellular organelles in regulating Ca2+dynamic oscillation. Mitochondrial calcium uniporter (MCU) is the primary mediator of Ca2+influx into mitochondria, manipulating cell energy metabolism, ROS production, and programmed cell death, all of which are critical for carcinogenesis. The understanding of the uniporter complex was significantly boosted by recent groundbreaking discoveries that identified the uniporter pore‐forming subunit MCU and its regulatory molecules, including MCU‐dominant negative β subunit (MCUb), essential MCU regulator (EMRE), MCU regulator 1 (MCUR1), mitochondrial calcium uptake (MICU) 1, MICU2, and MICU3. These provide the means and molecular platform to investigate MCU complex (uniplex)‐mediated impaired Ca2+signalling in physiology and pathology. This review aims to summarize the progress of the understanding regulatory mechanisms of uniplex, roles of uniplex‐mediated Ca2+signalling in cancer, and potential pharmacological inhibitors of MCU.
- 1 September 2018
- Published by Elsevier in Cancer Letters
- Vol. 432, 169-179
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma
- 1 September 2018
- Published by Elsevier in Cancer Letters
- Vol. 432, 169-179
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma
- Open Access
- 16 August 2018
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 48 (6) , 2302-2317
PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells
Background/Aims: Multidrug resistance (MDR) induced by the ABC transporter subfamily B member 1 (ABCB1) and subfamilyG member 2 (ABCG2) limits successful cancer chemotherapy and no commercially available MDR modulator is used in the clinic. In the current study, we aimed to investigate the effects of PCI29732 on the enhancement of chemotherapeutic agents. Methods: Cell cytotoxicity and reversal effect were measured with MTT assay. Additionally, flow cytometry was employed to detect the accumulation and efflux of the drugs. We investigated the interaction of PCI29732 and the substrate binding sites of ABCG2 was investigated via the photo-labeling of ABCG2 with the [125I] iodoarylazidoprazosin. The vanadate-sensitive ATPase activity of ABCG2 was measured to identify whether the drug affected the ATPase activity. RT-PCR and Western blot were utilized to analyze mRNA and protein expression respectively. Results: Here, we found that PCI29732 significantly enhanced the efficacy of substrate chemotherapeutic agents in ABCG2-overexpressing cells and also in xenografts harboring the H460/MX20 cell that overexpress ABCG2, but not in their parental sensitive cells and ABCB1-overexpressing cells. Mechanistically, the intracellular accumulations of doxorubicin and Rhodamine 123 were increased in ABCG2-overexpressing S1-MI-80 cells with the presence of PCI29732. PCI29732 stimulated the ATPase activity of ABCG2 at low concentrations. However at the high concentrations, PCI29732 inhibited the ATPase activity, and competed with [125I]-iodoarylazidoprazosin for photo-affinity labeling of ABCG2. PCI29732 did neither alter the mRNA or protein expression levels of ABCG2 nor the phosphorylation levels of AKT and ERK1/2. Conclusion: Our study demonstrates that PCI29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents, This findings encourages the development of combinational chemotherapy for the treatment of ABCG2- overexpressing cancer patients.
- 16 August 2018
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 48 (6) , 2302-2317
Open AccessPCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells
Background/Aims: Multidrug resistance (MDR) induced by the ABC transporter subfamily B member 1 (ABCB1) and subfamilyG member 2 (ABCG2) limits successful cancer chemotherapy and no commercially available MDR modulator is used in the clinic. In the current study, we aimed to investigate the effects of PCI29732 on the enhancement of chemotherapeutic agents. Methods: Cell cytotoxicity and reversal effect were measured with MTT assay. Additionally, flow cytometry was employed to detect the accumulation and efflux of the drugs. We investigated the interaction of PCI29732 and the substrate binding sites of ABCG2 was investigated via the photo-labeling of ABCG2 with the [125I] iodoarylazidoprazosin. The vanadate-sensitive ATPase activity of ABCG2 was measured to identify whether the drug affected the ATPase activity. RT-PCR and Western blot were utilized to analyze mRNA and protein expression respectively. Results: Here, we found that PCI29732 significantly enhanced the efficacy of substrate chemotherapeutic agents in ABCG2-overexpressing cells and also in xenografts harboring the H460/MX20 cell that overexpress ABCG2, but not in their parental sensitive cells and ABCB1-overexpressing cells. Mechanistically, the intracellular accumulations of doxorubicin and Rhodamine 123 were increased in ABCG2-overexpressing S1-MI-80 cells with the presence of PCI29732. PCI29732 stimulated the ATPase activity of ABCG2 at low concentrations. However at the high concentrations, PCI29732 inhibited the ATPase activity, and competed with [125I]-iodoarylazidoprazosin for photo-affinity labeling of ABCG2. PCI29732 did neither alter the mRNA or protein expression levels of ABCG2 nor the phosphorylation levels of AKT and ERK1/2. Conclusion: Our study demonstrates that PCI29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents, This findings encourages the development of combinational chemotherapy for the treatment of ABCG2- overexpressing cancer patients.
- Open Access
- 4 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-11
Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy
Various types of nanoparticles have been proposed for targeted drug delivering, imaging, and tracking of therapeutic agents. However, highly biocompatible nanoparticles with structure-induced fluorescence and capability to conjugate with biomarkers and drugs remain lacking. This research proposes and synthesizes fluorescent nanoparticles (f-PNPs) assembled by cyclic peptides to combine imaging and drug delivering for esophageal cancer (EC). To achieve tumor targeting, f-PNPs are first conjugated with RGD moieties to selectively target EC cells via αvβ3 integrin; the nanoparticles are then embedded with epirubicin (EPI). Cell viability assays and analysis of tissue histology reveal that EPI-loaded RGD-f-PNPs (RGD-f-PNPs/EPI) led to significantly reduced cardiotoxicity and improved anti-tumor activity compared to EPI alone. Moreover, the drug delivery to tumor sites and therapeutic responses could be monitored with near-infrared fluorescence using RGD-f-PNPs/EPI. This unique nanoparticle system may lead to potential approaches for bioorganic fluorescence-based delivering, imaging, and drug release tracking.
- 4 July 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-11
Open AccessNear infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy
Various types of nanoparticles have been proposed for targeted drug delivering, imaging, and tracking of therapeutic agents. However, highly biocompatible nanoparticles with structure-induced fluorescence and capability to conjugate with biomarkers and drugs remain lacking. This research proposes and synthesizes fluorescent nanoparticles (f-PNPs) assembled by cyclic peptides to combine imaging and drug delivering for esophageal cancer (EC). To achieve tumor targeting, f-PNPs are first conjugated with RGD moieties to selectively target EC cells via αvβ3 integrin; the nanoparticles are then embedded with epirubicin (EPI). Cell viability assays and analysis of tissue histology reveal that EPI-loaded RGD-f-PNPs (RGD-f-PNPs/EPI) led to significantly reduced cardiotoxicity and improved anti-tumor activity compared to EPI alone. Moreover, the drug delivery to tumor sites and therapeutic responses could be monitored with near-infrared fluorescence using RGD-f-PNPs/EPI. This unique nanoparticle system may lead to potential approaches for bioorganic fluorescence-based delivering, imaging, and drug release tracking.
- Open Access
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 404-416
Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1
Zinc, an essential micronutrient, has a cancer preventive role. Zinc deficiency has been shown to contribute to the progression of esophageal cancer. Orai1, a store‐operated Ca 2+ entry (SOCE) channel, was previously reported to be highly expressed in tumor tissues removed from patients with esophageal squamous cell carcinoma (ESCC) with poor prognosis, and elevation of its expression contributes to both hyperactive intracellular Ca 2+ oscillations and fast cell proliferation in human ESCC cells. However, the molecular basis of cancer preventive functions of zinc and its association with Orai1‐mediated cell proliferation remains unknown. The present study shows that zinc supplementation significantly inhibits proliferation of ESCC cell lines and that the effect of zinc is reversible with N,N,N′,N ′‐tetrakis (2‐pyridylmethyl) ethylenediamine, a specific Zn 2+ chelator, whereas non‐ tumorigenic esophageal epithelial cells are significantly less sensitive to zinc treatment. Fluorescence live cell imaging revealed that extracellular Zn 2+ exerted rapid inhibitory effects on Orai1‐mediated SOCE and on intracellular Ca 2+ oscillations in the ESCC cells. Knockdown of Orai1 or expression of Orai1 mutants with compromised zinc binding significantly diminished sensitivity of the cancer cells to zinc treatment in both SOCE and cell proliferation analyses. These data suggest that zinc may inhibit cell proliferation of esophageal cancer cells through Orai1‐mediated intracellular Ca 2+ oscillations and reveal a possible molecular basis for zinc‐induced cancer prevention and Orai1‐SOCE signaling pathway in cancer cells.—Choi, S., Cui, C., Luo, Y., Kim, S.‐H., Ko, J.‐K., Huo, X., Ma, J., Fu, L.‐W., Souza, R. F., Korichneva, I., Pan, Z. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. FASEB J. 32,404‐416 (2018). www.fasebj.org
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 404-416
Open AccessSelective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1
Zinc, an essential micronutrient, has a cancer preventive role. Zinc deficiency has been shown to contribute to the progression of esophageal cancer. Orai1, a store‐operated Ca 2+ entry (SOCE) channel, was previously reported to be highly expressed in tumor tissues removed from patients with esophageal squamous cell carcinoma (ESCC) with poor prognosis, and elevation of its expression contributes to both hyperactive intracellular Ca 2+ oscillations and fast cell proliferation in human ESCC cells. However, the molecular basis of cancer preventive functions of zinc and its association with Orai1‐mediated cell proliferation remains unknown. The present study shows that zinc supplementation significantly inhibits proliferation of ESCC cell lines and that the effect of zinc is reversible with N,N,N′,N ′‐tetrakis (2‐pyridylmethyl) ethylenediamine, a specific Zn 2+ chelator, whereas non‐ tumorigenic esophageal epithelial cells are significantly less sensitive to zinc treatment. Fluorescence live cell imaging revealed that extracellular Zn 2+ exerted rapid inhibitory effects on Orai1‐mediated SOCE and on intracellular Ca 2+ oscillations in the ESCC cells. Knockdown of Orai1 or expression of Orai1 mutants with compromised zinc binding significantly diminished sensitivity of the cancer cells to zinc treatment in both SOCE and cell proliferation analyses. These data suggest that zinc may inhibit cell proliferation of esophageal cancer cells through Orai1‐mediated intracellular Ca 2+ oscillations and reveal a possible molecular basis for zinc‐induced cancer prevention and Orai1‐SOCE signaling pathway in cancer cells.—Choi, S., Cui, C., Luo, Y., Kim, S.‐H., Ko, J.‐K., Huo, X., Ma, J., Fu, L.‐W., Souza, R. F., Korichneva, I., Pan, Z. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. FASEB J. 32,404‐416 (2018). www.fasebj.org